Edward Md Kaye Sells 1,029 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Key Points

• Edward Md Kaye, Director of Stoke Therapeutics, sold 1,029 shares at an average price of $20.00, reducing his ownership by 0.67% but still retaining 152,441 shares valued at approximately $3 million.
• The company reported earnings of ($0.40) per share for the last quarter, beating analysts' expectations, but revenue was below estimates at $13.82 million.
• Several research firms have raised their price targets for Stoke Therapeutics, with average target set at $25.57 and a consensus rating of "Buy".

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Edward Md Kaye sold 1,029 shares of Stoke Therapeutics stock in a transaction on Friday, August 29th. The shares were sold at an average price of $20.00, for a total value of $20,580.00. Following the completion of the sale, the director directly owned 152,441 shares of the company's stock, valued at $3,048,820. The trade was a 0.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Stoke Therapeutics Trading Up 0.9%

NASDAQ:STOK traded up $0.18 during midday trading on Wednesday, reaching $19.77. The company had a trading volume of 1,307,730 shares, compared to its average volume of 810,410. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of 23.26 and a beta of 1.14. The stock's fifty day simple moving average is $14.42 and its 200-day simple moving average is $10.83. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $20.45.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. The firm had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. As a group, sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its stake in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock worth $50,000 after buying an additional 3,591 shares in the last quarter. Corient Private Wealth LLC acquired a new stake in Stoke Therapeutics during the 2nd quarter valued at $7,489,000. Opaleye Management Inc. grew its holdings in Stoke Therapeutics by 87.4% during the 2nd quarter. Opaleye Management Inc. now owns 562,120 shares of the company's stock valued at $6,380,000 after buying an additional 262,120 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in Stoke Therapeutics during the 2nd quarter valued at $156,000. Finally, Gilder Gagnon Howe & Co. LLC grew its holdings in Stoke Therapeutics by 22.4% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 129,571 shares of the company's stock valued at $1,471,000 after buying an additional 23,754 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have recently issued reports on STOK. Wedbush upped their price objective on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 13th. Jefferies Financial Group started coverage on Stoke Therapeutics in a research note on Friday, July 18th. They set a "buy" rating and a $30.00 target price for the company. Chardan Capital reiterated a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. BTIG Research set a $28.00 price objective on shares of Stoke Therapeutics and gave the stock a "buy" rating in a report on Monday, August 18th. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Two equities research analysts have rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $25.57.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.